# Vasundhara Ras (NSE: VRL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VRL · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹53 Cr, it ranks 3040th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Chemicals.

In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹12 Cr (+53.2% year on year) and net profit ₹2 Cr (+451.1%), on a standalone basis. Promoters held 61.98% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹53 Cr |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹12 Cr | +53.2% | ₹2 Cr | +451.1% | ₹7.80 |
| Q3 FY26 | ₹7 Cr | −15.5% | ₹1 Cr | −50.3% | ₹2.27 |
| Q2 FY26 | ₹9 Cr | −9.8% | ₹2 Cr | +40.1% | ₹6.47 |
| Q1 FY26 | ₹8 Cr | −0.9% | ₹1 Cr | −33.7% | ₹1.80 |
| Q4 FY25 | ₹8 Cr | −30.3% | ₹0 Cr | −78.9% | ₹1.43 |
| Q3 FY25 | ₹9 Cr | +7.2% | ₹1 Cr | +5.1% | ₹4.57 |
| Q2 FY25 | ₹10 Cr | +4.9% | ₹1 Cr | +5.8% | ₹4.61 |
| Q1 FY25 | ₹8 Cr | −8.4% | ₹1 Cr | −10.4% | ₹2.71 |

## Shareholding (30 Jun 2026)

- Promoters: 61.98%
- Non-institutions: 38.02%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Constronics Inf](https://app.pivotnow.in/stock/CONSTRONIC) | — | ₹57 Cr | — | — |
| [Kabra Drugs](https://app.pivotnow.in/stock/KABRADG) | — | ₹56 Cr | — | — |
| [Bandaram Pharma](https://app.pivotnow.in/stock/BANDARAM) | — | ₹53 Cr | — | — |
| [Vivimed Labs](https://app.pivotnow.in/stock/VIVIMEDLAB) | ₹6.21 | ₹51 Cr | — | — |
| [Shree Pacetroni](https://app.pivotnow.in/stock/SHREEPAC) | — | ₹50 Cr | — | — |
| [Biofil Chemicals & Pharmaceuticals](https://app.pivotnow.in/stock/BIOFILCHEM) | ₹30.00 | ₹49 Cr | 17.5 | — |

## Questions and answers

### What is the market cap of Vasundhara Ras?

Vasundhara Ras' market capitalisation is ₹53 Cr (₹53 Cr) at the 22 Oct 2026 close, ranking 3040th among the NSE companies Pivot tracks.

### What were Vasundhara Ras' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Vasundhara Ras reported revenue of ₹12 Cr, +53.2% year on year, and net profit of ₹2 Cr, +451.1% year on year.

### What is the shareholding pattern of Vasundhara Ras?

As of 30 Jun 2026: promoters 61.98%, non-institutions 38.02%.

### Who are Vasundhara Ras' competitors?

The listed Pharma & Healthcare companies closest to Vasundhara Ras by market cap are Constronics Inf, Kabra Drugs, Bandaram Pharma, Vivimed Labs, Shree Pacetroni and Biofil Chemicals & Pharmaceuticals.

### Is Vasundhara Ras a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Vasundhara Ras' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VRL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.